Skip to content

    Recently Viewed

      Listening...

      Our Company

      Our statement on the Los Angeles talc verdict

      Share Article
      share to
      Baby Powder

      “Ovarian cancer is a devastating diagnosis and we deeply sympathize with the women and families impacted by this disease. We will appeal today’s verdict because we are guided by the science, which supports the safety of Johnson’s Baby Powder. In April, the National Cancer Institute’s Physician Data Query Editorial Board wrote, ‘The weight of evidence does not support an association between perineal talc exposure and an increased risk of ovarian cancer.’ We are preparing for additional trials in the U.S. and we will continue to defend the safety of Johnson’s Baby Powder.” - Carol Goodrich, Global Media Relations, Johnson & Johnson Consumer, Inc.

      For more information, please also see: 5 important facts about the safety of talc

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.